Category Archives: Stem Cell Medicine

Global Leukapheresis Market is Expected to Reach at a CAGR of 9.60% from 2018 to 2025 – PharmiWeb.com

A new research report published by Fior Markets with the titleGlobal Leukapheresis Market by Type (Leukapheresis Devices, Leukapheresis Disposables), Application, End-Users, and Region and Global Forecast 2018-2025.

As per the report, theglobal leukapheresis marketis expected to grow from USD 19.29 Million in 2017 to USD 41.07 Million by 2025 at a CAGR of 9.60% during the forecast period from 2018-2025. Asia Pacific is expected to dominate the market during the forecast period. Ongoing regenerative medicine research in the region, rise in the number of clinical trials and the presence of leading pharma and biotech companies in the region are some of the major factors driving the growth of the market in region.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/375981/request-sample

Prominent players operating in the market are Asahi Kasei Medical Co., Ltd, Macopharma SA, Fresenius Se & Co. KGaA, Bioivt, Haemonetics Corporation, PPA Research Group, Inc., Hemacare Corporation, Key Biologics, LLC, Terumo BCT, ALLCells, LLC, Stemexpress, LLC, Stemcell Technologies, Inc., Caltag Medsystems Limited, Zenbio, Inc, Precision for Medicine, Inc and others. Major firms are incorporating various strategies to increase their market reach. For instance, in April 2018, Fresenius Kabi expanded its production site for medical devices in Dominican Republic (U.S). This plant manufactures and exports apheresis systems for plasma and platelet collection. This new production facility has enhanced its production capabilities to meet the demand for apheresis systems.

The type segment is classified into leukapheresis devices and leukapheresis disposables. The leukapheresis disposables segment accounted for the largest market share in 2017. The increasing applications for the isolation of primary cells from blood for cell therapy research applications is estimated to drive the growth of the segment. Applications segment is divided into research applications and therapeutic applications. The research applications segment is dominating and was valued around USD 11.13 million in 2017. Growing adoption in research activities for cancer, immunology, infectious diseases, drug discovery, regenerative medicine, and cell-based therapies are contributing to the growth of the segment. End user segment is classified into blood component providers and blood centers, academic and research institutes, pharmaceutical and biotechnology companies and hospitals and transfusion centers. The blood component providers & blood centers segment is expected to grow with the highest CAGR in the forecast period. Increasing number of blood donations and rising demand for leukopaks in clinical conditions like cancer are driving the growth.

Increasing prevalence of leukemia and rise in the blood donations are boosting demand of market in forecast period. In addition, research activities including development of cell-based immunotherapies is also boosting the growth of the market. High costs of leukapheresis may restrict the growth of the market. However, innovations in R&D activities and commercialization of new products are propelling the growth of the market in forecast period.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/global-leukapheresis-market-by-type-leukapheresis-devices-leukapheresis-375981.html

About the report: The globalleukapheresis market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report: The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us Mark Stone Phone:+1-201-465-4211 Email:sales@fiormarkets.com Web:www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Read more:
Global Leukapheresis Market is Expected to Reach at a CAGR of 9.60% from 2018 to 2025 - PharmiWeb.com

Sweet! Rice researchers 3D print blood vessels using sugar and laser – 3DPMN

Powdered sugar is the special ingredient in a Rice University recipe for mimicking the bodys intricate, branching blood vessels in lab-grown tissues. This approach to sugar 3D printed blood vessels is not entirely new: sugar has already been used in experiments with selective laser sintering and in bioprinting. In theresearch published in the journal Nature Biomedical Engineering, Rice bioengineers showed they could keep densely packed cells alive for two weeks in relatively large constructs by creating complex blood vessel networks from templates of 3D printed sugar.

One of the biggest hurdles to engineering clinically relevant tissues is packing a large tissue structure with hundreds of millions of living cells, said study lead author Ian Kinstlinger, a bioengineering graduate student in RicesBrown School of Engineering. Delivering enough oxygen and nutrients to all the cells across that large volume of tissue becomes a monumental challenge.

Kinstlinger explains that nature solved this problem through the evolution of complex vascular networks, which weave through our tissues and organs in patterns reminiscent of tree limbs. The vessels simultaneously become smaller in thickness but greater in number as they branch away from a central trunk, allowing oxygen and nutrients to be efficiently delivered to cells throughout the body.

By developing new technologies and materials to mimic naturally occurring vascular networks, were getting closer to the point that we can provide oxygen and nutrients to a sufficient number of cells to get meaningful long-term therapeutic function, Kinstlinger said.

The sugar templates were 3D-printed with an open-source, modified laser cutter in the lab of study co-author Jordan Miller, an assistant professor of bioengineering at Rice. The 3D-printing process we developed here is like making a very precise creme brulee, said Miller, whose original inspiration for the project wasan intricate dessert.

Miller said the complex, detailed structures are made possible by selective laser sintering, a 3D-printing process that fuses minute grains of powder into solid 3D objects. In contrast to more common extrusion 3D printing, where melted strands of material are deposited through a nozzle, laser sintering works by gently melting and fusing small regions in a packed bed of dry powder. Both extrusion and laser sintering build 3D shapes one 2D layer at a time, but the laser method enables the generation of structures that would otherwise be prone to collapse if extruded, he said.

There are certain architectures such as overhanging structures, branched networks and multi vascular networks which you really cant do well with extrusion printing, said Miller, who demonstrated the concept of sugar templating with a 3D extrusion printer during his postdoctoral studies at the University of Pennsylvania. Miller began work on the laser-sintering approach shortly after joining Rice in 2013.

Sugar is especially useful in creating blood vessel templates because its durable when dry, and it rapidly dissolves in water without damaging nearby cells. To make tissues, Kinstlinger uses a special blend of sugars to print templates and then fills the volume around the printed sugar network with a mixture of cells in liquid gel. The gel becomes semisolid within minutes, and the sugar is then dissolved and flushed away to leave an open passageway for nutrients and oxygen.

A major benefit of this approach is the speed at which we can generate each tissue structure, Kinstlinger said. We can create some of the largest tissue models yet demonstrated, in under five minutes.

Miller said the new study answers two important questions: What sugars can be sintered into coherent structures, and what computational algorithms can derive complex, branching architectures that mimic those found in nature?

The computational algorithm that generated the treelike vascular architectures in the study was created in collaboration withNervous System, a design studio that uses computer simulation to make unique art, jewelry and housewares that are inspired by patterns found in nature.

Were using algorithms inspired by nature to create functional networks for tissues, said Jessica Rosenkrantz, co-founder and creative director of Nervous System and a study co-author. Because our approach is algorithmic, its possible to create customized networks for different uses.

After creating tissues patterned with these computationally generated vascular architectures, the team demonstrated the seeding of endothelial cells inside the channels and focused on studying the survival and function of cells grown in the surrounding tissue, including rodent liver cells called hepatocytes. The hepatocyte experiments were conducted in collaboration with University of Washington (UW) bioengineer and study co-authorKelly Stevens, whose research group specializes in studying the delicate cells, which are notoriously difficult to maintain outside the body.

This method could be used with a much wider range of material cocktails than many other bioprinting technologies, Stevens said. This makes it incredibly versatile.

Miller said, We showed that perfusion through 3D vascular networks allows us to sustain these large liverlike tissues. While there are still long-standing challenges associated with maintaining hepatocyte function, the ability to both generate large volumes of tissue and sustain the cells in those volumes for sufficient time to assess their function is an exciting step forward.

Stevens is an assistant professor of bioengineering in the UW College of Engineering, assistant professor of pathology in the UW School of Medicine and an investigator at theUW MedicineInstitute for Stem Cell and Regenerative Medicine.

Additional authors include Gisele Calderon, Karen Vasquez Ruiz, David Yalacki, Palvasha Deme, Kevin Janson, Daniel Sazer and Saarang Panchavati, all of Rice; Sarah Saxton and Fredrik Johansson, both of UW; Jesse Louis-Rosenberg of Nervous System; and Karl-Dimiter Bissig of Baylor College of Medicine.

The work was supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, the National Institutes of Health (HL134510, DK115461, DP2HL137188, T32EB001650, HL140905) and the Cancer Prevention and Research Institute of Texas via the Texas Hepatocellular Carcinoma Consortium (CPRIT RP150587).

More:
Sweet! Rice researchers 3D print blood vessels using sugar and laser - 3DPMN

Regenerative Medicine Market 2020 | Covid19 Impact Analysis | Business Outlook, Growth, Revenue, Trends and Forecasts 2026 | Acelity LP Inc., Nuvasive…

Global Regenerative Medicine Market valued approximately USD 49.68 billion in 2018 is anticipated to grow with a healthy growth rate of more than 24.2% over the forecast period 2019-2026.

Regenerative Medicine Market describes an in-depth evaluation and professional Covid-19 Outbreak study on the present and future state of the Regenerative Medicine market across the globe, including valuable facts and figures. Regenerative Medicine Market provides information regarding the emerging opportunities in the market & the market drivers, trends & upcoming technologies that will boost these growth trends. The report provides a comprehensive overview including Definitions, Scope, Application, Production and CAGR (%) Comparison, Segmentation by Type, Share, Revenue Status and Outlook, Capacity, Consumption, Market Drivers, Production Status and Outlook and Opportunities, Export, Import, Emerging Markets/Countries Growth Rate. The report presents a 360-degree overview of the competitive landscape of the industries. The Regenerative Medicine market report assesses the key regions (countries) promising a huge market share for the forecast period.

Top Key players of Regenerative Medicine Market Covered In The Report: Acelity L.P. Inc. Nuvasive Inc. Vericel Corporation Osiris Therapeutics Inc. Stryker Corporation Medtronic PLC Key Market Segmentation of Regenerative Medicine:

By Technology:

Stem Cell Therapy Biomaterial Tissue Engineering Others

By Application:

Bone Graft Substitutes Osteoarticular Diseases Dermatology Cardiovascular Central Nervous System Others

The Regenerative Medicine report gives detail complete examination to territorial sections that covered The USA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, and Rest of World in Global Outlook Report with Regenerative Medicine Market definitions, characterizations, delivering reports, cost structures, advancement strategies, and plans. The results and information are top notches in the Regenerative Medicine report utilizing outlines, diagrams, pie graphs, and other pictorial portrayals concerning its Current Trends, Dynamics, and Regenerative Medicine Business Scope, Key Statistics and CAGR Analysis of top key players.

Buy Full Report Now @ https://www.qurateresearch.com/report/buy/HnM/global-regenerative-medicine-market/QBI-BRC-HnM-435840/

(A free report data (as a form of Excel Datasheet) will also be provided upon request along with a new purchase.)

Key Highlights from Regenerative Medicine Market Study:

Income and Sales Estimation Historical Revenue and deals volume is displayed and supports information is triangulated with best down and base up ways to deal with figure finish market measure and to estimate conjecture numbers for key areas shrouded in the Regenerative Medicine report alongside arranged and very much perceived Types and end-utilize industry. Moreover, macroeconomic factor and administrative procedures are discovered explanation in Regenerative Medicine industry advancement and perceptive examination.

Assembling Analysis The Regenerative Medicine report is presently broke down concerning different types and applications. The Regenerative Medicine market gives a section featuring the assembling procedure examination approved by means of essential data gathered through Industry specialists and Key authorities of profiled organizations.

Competition Analysis Regenerative Medicine Leading players have been considered relying upon their organization profile, item portfolio, limit, item/benefit value, deals, and cost/benefit.

Demand and Supply and Effectiveness Regenerative Medicine report moreover gives support, Production, Consumption and (Export and Import).

Which prime data figures are included in the report? -Market size (Last few years, current and expected) -Market share analysis as per different companies) -Market forecast) -Demand) -Price Analysis) -Market Contributions (Size, Share as per regional boundaries)

Who all can be benefitted out of this report? -Market Investigators -Teams, departments, and companies -Competitive organizations -Individual professionals -Vendors, Buyers, Suppliers -Others

What are the crucial aspects incorporated in the report? -Industry Value Chain -Consumption Data -Market Size Expansion -Key Economic Indicators

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Regenerative Medicine market.

Chapter 2: Evaluating the leading manufacturers of the global Regenerative Medicine market which consists of its revenue, sales, and price of the products.

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales.

Chapter 4: Presenting global Regenerative Medicine market by regions, market share and with revenue and sales for the projected period.

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Contact Us:

Web:www.qurateresearch.com E-mail:[emailprotected] Ph: US +13393375221

Note: In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Visit link:
Regenerative Medicine Market 2020 | Covid19 Impact Analysis | Business Outlook, Growth, Revenue, Trends and Forecasts 2026 | Acelity LP Inc., Nuvasive...

Regenerative Medicine Products Market, Share, Growth, Trends And Forecast To 2025 UpMarketResearch – 3rd Watch News

Regenerative Medicine Products Market Forecast 2020-2026

The Global Regenerative Medicine Products Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Regenerative Medicine Products Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/107455

The Report Covers the Following Companies: Acelity DePuy Synthes Medtronic ZimmerBiomet Stryker MiMedx Group Organogenesis UniQure Cellular Dynamics International Osiris Therapeutics Vcanbio Gamida Cell Golden Meditech Cytori Therapeutics Celgene Vericel Corporation Guanhao Biotech Mesoblast Stemcell Technologes Bellicum Pharmaceuticals

By Types: Cell Therapy Tissue Engineering Biomaterial Others

By Applications: Dermatology Cardiovascular CNS Orthopedic Others

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/107455

Years Considered to Estimate the Market Size: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year: 2020-2026

Important Facts about Regenerative Medicine Products Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/107455

About UpMarketResearch: Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearch Name Alex Mathews Email [emailprotected] Organization UpMarketResearch Address 500 East E Street, Ontario, CA 91764, United States.

View post:
Regenerative Medicine Products Market, Share, Growth, Trends And Forecast To 2025 UpMarketResearch - 3rd Watch News

Reven Announces the Appointment of Eminent Physician-Scientist Fatih M. Uckun, M.D., Ph.D., Internationally Recognized for His Seminal Contributions…

GOLDEN, Colo.--(BUSINESS WIRE)--Reven Holdings, Inc. (Reven), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnessesincluding COVID-19and inflammatory disorders, today announced the appointment of Dr. Fatih M. Uckun as its Chief Medical Officer and Chief Scientific Officer.

In his new position at Reven, Dr. Uckun will provide executive oversight for Revens global Research & Development and clinical programs. In addition, Dr. Uckun will contribute medical-scientific leadership and direction for Revens basic and translational research activities, R&D and clinical development programs in cancer, transplantation immunology, sepsis, metabolic disorders, inflammatory disorders, and the acute respiratory distress syndrome (ARDS) in patients with sepsis, including COVID-19 patients with viral sepsis.

Dr. Uckun stated, It is an exceptionally exciting time to join Reven to support a global registration strategy for its unique RJX platform. The components of RJX exhibited very promising activity in clinical studies involving ARDS patients and non-clinical studies in animal models of ARDS. The published data from these clinical, and recent non-clinical, studies confirming its unique mechanism of action, provide the medical-scientific rationale for Revens clinical development strategy for RJX. The clinical study in COVID-19 patients is a logical next step. I very much look forward to working with the talented and experienced leadership team of Reven and our collaborators. The goal is to diligently advance the RJX clinical trial program with the vision of developing RJX-based new treatments for COVID-19 patients, as well as patients with difficult-to-treat forms of cancer and inflammatory disorders who are in urgent need for therapeutic innovations.

As we move forward with our planned clinical trial of Rejuveinix (RJX) for treatment of COVID-19, Dr. Uckuns decades of drug development experience will be critical in successful execution and the establishment of effective collaborations with other stakeholders, said Peter Lange, Chief Executive Officer of Reven. Dr. Uckun embodies Revens core values: dedication to patients, passion for science, and excellence in execution. I am delighted to have the opportunity to welcome Dr. Uckun as part of Revens leadership team.

About Dr. Uckun

Dr. Uckun is an elected Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations. He received numerous awards for his work on monoclonal antibodies, recombinant cytokines and fusion proteins, radiation sensitizers, kinase inhibitors and targeted therapeutics for difficult-to-treat cancers, including the Stohlman Memorial Award of the Leukemia Society of America, the highest honor given to a Leukemia Society Scholar. He has served as a member of several editorial boards and National Institutes of Health grant review/special emphasis panels.

Dr. Uckun earned his doctoral degrees at the University of Heidelberg, Germany, where he also served as an active member of the autologous bone marrow transplant and peripheral stem cell transplant clinical research teams of the Tumor Center. Dr. Uckun completed his residency training in pediatrics, clinical fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology and microbiology at the University of Minnesota. Dr. Uckun has more than thirty years of professional experience in developmental therapeutics with a special emphasis on targeted therapeutics/precision medicines and biopharmaceuticals. He has published more than 500 peer-reviewed papers, authored numerous review articles and book chapters, and is an inventor on numerous patents.

For eleven years, Dr. Uckun worked as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy. At the Keck School of Medicine of the University of Southern California, he was a Professor and Head of Translational Research in Leukemia and Lymphoma of the CCBD and a Principal Investigator of the Stem Cell-Regenerative Medicine Initiative for six years. From 2012 to 2015, Dr. Uckun served as chair of the Biotargeting Working Group and a Member of the Coordination and Governance Committee of the National Cancer Institute Alliance for Nanotechnology in Cancer.

Dr. Uckun has held executive positions in multiple biotechnology companies and has extensive regulatory experience. Prior to joining Reven, Dr. Uckun served as Vice President of Scientific Solutions at Worldwide Clinical Trials, Chief Medical Officer of Oncotelic and Mateon Therapeutics, Head of Immuno-Oncology at Ares Pharmaceuticals, and as Executive Medical Director and Strategy Lead in Global Oncology and Hematology at Syneos Health. Previously, he was Vice President of Research and Clinical Development at Nantkwest, and Chief Scientific Officer of both Jupiter Research Institute and Paradigm Pharmaceuticals. Dr. Uckun is a former Vice Chair of the New Agents Committee as well as a Member of the Leukemia Steering Committee of the Childrens Cancer Study Group, an NCI-funded cooperative clinical trials consortium that coordinated pediatric and adolescent/young adult leukemia trials at 120 institutions in the U.S., Canada, Australia and Europe.

Dr. Uckun has deep knowledge and experience in the treatment of infectious diseases and their complications. In particular, he has extensive experience in viral, fungal, and bacterial infections of immunocompromised hosts, septic shock, ARDS, systemic capillary leak syndrome and cytokine release syndrome (CRS). He served as the Principal Investigator of a virus neutralizer project funded by the Defense Advanced Research Projects Agency (DARPA) as part of its unconventional countermeasures program. Dr. Uckun directed several federally funded virology/innate immunity projects and published numerous peer-reviewed papers on RNA viruses and anti-viral agents.

About Rejuveinix (RJX)

RJX is an intravenous (IV) formulation of known physiologically compatible compounds that is being developed for more effective supportive therapy of patients with sepsis, including COVID-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS). The RJX formulation is a solution of buffered acid products, electrolyte components, and vitamins, including ascorbic acid, cyanocobalamin, thiamine hydrochloride, riboflavin 5 phosphate, niacinamide, pyridoxine hydrochloride, and calcium d-pantothenate, and magnesium sulfate heptahydrate, a mineral with a negative oxidation-reduction potential. The components of RJX exhibited promising activity in clinical studies involving ARDS patients and/or non-clinical studies in animal models of ARDS. The published data from these clinical and non-clinical studies provided the medical-scientific rationale for Revens clinical development strategy for RJX and a clinical study in COVID-19 patients. The clinical tolerability of RJX was confirmed in a recently completed double blind, placebo-controlled Phase 1 dose-escalation study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105).

About Reven Holdings, Inc.

Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado-based operating company Reven, LLC, is a biopharmaceutical company. Revens vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.

Revens Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as may, on-track, expect, anticipate hope, vision, optimism, design, exciting, promising, will, conviction, estimate, intend, believe and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the companys product candidates and the potential use of the companys product candidates to treat various disease indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing market competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. These risks are not exhaustive; the company faces known and unknown risks, including the risk factors described in the companys periodic SEC filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information regarding future events, or otherwise.

Continue reading here:
Reven Announces the Appointment of Eminent Physician-Scientist Fatih M. Uckun, M.D., Ph.D., Internationally Recognized for His Seminal Contributions...

Global and Country Specific CRISPR And CRISPR Associated Genes Market Report 2020 Forecast, Opportunities and Strategies To 2027: COVID 19 Impact and…

CRISPR And CRISPR Associated Genes Market report involves all together a different chapter on COVID 19 Impact. The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life Science, and many more. Trade barriers are further restraining the demand- supply outlook. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303. Download The report Copy form the webstie: https://cognitivemarketresearch.com/pharma-%26-healthcare/crispr-and-crispr-associated-genes-market-report

The major players profiled in this report include: Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich, Precision Biosciences, Genscript, Sangamo Biosciences Inc., Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, Origene Technologies

Market segment by type can be split into: Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich, Precision Biosciences, Genscript, Sangamo Biosciences Inc., Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, Origene Technologies, Market segment by Regions/Countries this report covers, North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, Market segment by Type the product can be split into, Genome Editing, Genetic engineering, GRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering

Market segment by the application can be split into: Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes

DOWNLOAD FREE SAMPLE REPORT@: https://cognitivemarketresearch.com/pharma-%26-healthcare/crispr-and-crispr-associated-genes-market-report#download_report

As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall CRISPR And CRISPR Associated Genes globally. This report on CRISPR And CRISPR Associated Genes provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcases market trends and forecast to 2027, factoring the impact of COVID-19 situation.

CRISPR And CRISPR Associated Genes Market report provide an in-depth understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, and opportunities in the market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of last three years. Moreover, the report also offers a 360 outlook of the market through the competitive landscape of the global industry player and helps the companies to garner CRISPR And CRISPR Associated Genes Market revenue by understanding the strategic growth approaches.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here> Download Sample Report of CRISPR And CRISPR Associated Genes Market Report 2020 (Coronavirus Impact Analysis on CRISPR And CRISPR Associated Genes Market)

Report provides industry analysis, important insights, and a competitive and useful advantage to the pursuers. The report analyzes different segments and offers the current and future prospects of each segment. Furthermore, this research report contains an in depth analysis of the top players with data such as product specification, company profiles and product picture, sales area, and base of manufacturing in the global CRISPR And CRISPR Associated Genes market. The impact on the supply and demand of the raw materials, due to the COVID-19 is also analyzed in the global CRISPR And CRISPR Associated Genes market.

Additionally, report consists of product life cycle, which discus about the current stage of product. Further, it adds manufacturing cost analysis as well as complete manufacturing process involved. Report also adds supply chain analysis to ensure complete data of market.

Objectives of CRISPR And CRISPR Associated Genes Market Report: To justifiably share in-depth info regarding the decisive elements impacting the increase of industry (growth capacity, chances, drivers and industry specific challenge and risks) To know the CRISPR And CRISPR Associated Genes Market by pinpointing its many sub segments To profile the important players and analyze their growth plans To endeavor the amount and value of the CRISPR And CRISPR Associated Genes Market sub-markets, depending on key regions (various vital states) To analyze the Global CRISPR And CRISPR Associated Genes Market concerning growth trends, prospects and also their participation in the entire sector To inspect and study the Global CRISPR And CRISPR Associated Genes Market size form the company, essential regions/countries, products and applications, background information and also predictions to 2027 Primary worldwide CRISPR And CRISPR Associated Genes Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans for the next coming years To examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market

Access Exclusive Free Sample Report (COVID-19 Impact Analysis Updated Edition): Click Here> Download Sample Report of CRISPR And CRISPR Associated Genes Market Report 2020 (Pandemic Impact Analysis Updated Edition May 2020)

Follow is the chapters covered in CRISPR And CRISPR Associated Genes Market: Chapter 1 CRISPR And CRISPR Associated Genes Market Overview Chapter 2 COVID 19 Impact Chapter 3 CRISPR And CRISPR Associated Genes Segment by Types (Product World) Chapter 4 Global CRISPR And CRISPR Associated Genes Segment by Application Chapter 5 Global CRISPR And CRISPR Associated Genes Market by Regions (2015-2027) Chapter 6 Global CRISPR And CRISPR Associated Genes Market Competition by Manufacturers Chapter 7 Company (Top Players) Profiles and Key Data Chapter 8 Global CRISPR And CRISPR Associated Genes Revenue by Regions (2015-2020) Chapter 9 Global CRISPR And CRISPR Associated Genes Revenue by Types Chapter 10 Global CRISPR And CRISPR Associated Genes Market Analysis by Application Chapter 11 North America CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 12 Europe CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 13 Asia Pacific CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 14 South America CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 15 Middle East & Africa CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 16 CRISPR And CRISPR Associated Genes Manufacturing Cost Analysis Chapter 17 Marketing Strategy Analysis, Distributors/ Traders Chapter 18 Global CRISPR And CRISPR Associated Genes Market Forecast (2020-2027) Chapter 19 Research Findings and Conclusion Get detailed TOC for CRISPR And CRISPR Associated Genes Market Report @ https://cognitivemarketresearch.com/pharma-%26-healthcare/crispr-and-crispr-associated-genes-market-report#table_of_contents.

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team, who will ensure that you get a report that suits your needs. You can also get in touch with our executives on to share your research requirements.nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market. Contact Us: +1-312-376-8303 Email: nicolas.shaw@cognitivemarketresearch.com Web: https://www.cognitivemarketresearch.com

**********Download the Entire Report************************************************* https://cognitivemarketresearch.com/pharma-%26-healthcare/crispr-and-crispr-associated-genes-market-report

Continued here:
Global and Country Specific CRISPR And CRISPR Associated Genes Market Report 2020 Forecast, Opportunities and Strategies To 2027: COVID 19 Impact and...

California voters: Here are the 12 measures on the November ballot – San Francisco Chronicle

Californians will see a lengthy list of initiatives and referendums on the November ballot.

Secretary of State Alex Padilla has assigned proposition numbers to 12 measures that have qualified for the ballot, from funding for stem cell research to a repeal of the states ban on affirmative action and an expansion of consumer privacy laws. Each must be approved by a simple majority to become law.

Proposition 14: Stem cell research. Would re-fund the California Institute for Regenerative Medicine, the states stem cell agency, by allowing it to issue $5.5 billion in bonds for research, training and facilities construction.

Proposition 15: Limits on property taxes. Would rewrite Proposition 13, the landmark 1978 measure that limits property tax increases and allows residential and commercial property to be reassessed only when it is sold.

Prop. 15 would boost property taxes on large commercial and industrial property by allowing it to be reappraised more frequently. The added money would go to school districts and local governments. Prop. 13 rules for residential property would be unchanged.

Proposition 16: Affirmative action. A constitutional amendment, proposed by state legislators, that would reverse Californias voter-approved 1996 ban on affirmative action. It would repeal Proposition 209, which prohibits public universities, schools and government agencies from using race or sex in their admissions criteria, hiring and contract decisions.

Proposition 17: Parolee voting. A constitutional amendment, proposed by state legislators, that would restore the voting rights of all people on parole if theyve completed their state or federal prison terms.

Proposition 18: Voting age. A constitutional amendment, proposed by state legislators, that would allow 17-year-olds to vote in primary elections if they would turn 18 before the general election.

Proposition 19: Property tax transfers. A constitutional amendment, proposed by state legislators, that would allow people age 55 and older, and victims of wildfires and other disasters, to keep lower property tax rates when they move to new homes.

Proposition 20: Criminal justice. Would make changes to the criminal justice system by revising two earlier initiatives, Proposition 47 and Proposition 57. The new measure would expand the list of violent crimes for which there is no early release, adding sex trafficking of a child and felony domestic violence. It would also require DNA collection for those convicted of several types of misdemeanors.

Proposition 21: Rent control. Would reverse a ban on local rent control laws. It would repeal the Costa-Hawkins Rental Housing Act, which prohibits cities from passing rent control ordinances for housing built since 1995. Voters overwhelmingly rejected a similar measure in 2018.

An earlier version of this story erroneously stated that two additional measures could qualify for the November ballot. The window for qualifying has closed.

Proposition 22: Gig worker classification. Would exempt app-based drivers, including those working for Uber, Lyft and DoorDash, from a state law that classifies gig workers as employees. The companies want to undo part of AB5, Californias gig-worker law, which aims to classify their drivers as employees and make them eligible for benefits. Under the ballot measure, the companies could keep drivers as independent contractors while granting them some benefits and earnings guarantees.

Proposition 23: Kidney dialysis clinics. Would increase state regulation of kidney dialysis clinics. Among the proposed requirements: Clinics would be prohibited from discriminating against patients based on their source of payment.

Proposition 24: Consumer data privacy. Would expand Californias consumer privacy law, passed in 2018. The measure would triple penalties for companies that break laws regarding the collection and sale of childrens private information. It would also create a state agency to enforce consumer privacy protections.

Proposition 25: Cash bail. Would overturn a 2018 law that eliminates cash bail as a requirement to release people from jail before trial.

Dustin Gardiner is a San Francisco Chronicle staff writer. Email: dustin.gardiner@sfchronicle.com Twitter: @dustingardiner

Dustin Gardiner is a state Capitol reporter for The San Francisco Chronicle. He joined The Chronicle in 2019, after nearly a decade with The Arizona Republic, where he covered state and city politics. Dustin won several awards for his reporting in Arizona, including the 2019 John Kolbe Politics Reporting award, and the 2017 Story of the Year award from the Arizona Newspapers Association. Outside of work, he enjoys hiking, camping, reading fiction and playing Settlers of Catan. He's a member of NLGJA, the association of LGBTQ journalists.

Outdoors

July 4th

COVID-19

Tenderloin

Giants

Original post:
California voters: Here are the 12 measures on the November ballot - San Francisco Chronicle

Quick and Simple Technology Enhances the Potential of Stem Cells To Differentiate Into Adult Cells – Technology Networks

Mouse embryoid body with multiple cell types (in different colours) generated in vitro after expression of miR-203 in stem cells. Credit: CNIO

Read Time:

Stem cells have been holding great promise for regenerative medicine for years. In the last decade, several studies have shown that this type of cell, which in Spanish is called mother cell because of its ability to give rise to a variety of different cell types, can be applied in regenerative medicine for diseases such as muscular and nervous system disorders, among others. Researchers and stem cell pioneers Sir John B. Gurdon and Shinya Yamanaka received the Nobel Prize in Physiology and Medicine in 2012 for this idea. However, one of the main limitations in the application of these cell therapies is the quality of the stem cells that can be generated in the laboratory, which impedes their use for therapeutic purposes. Now, a team from the Cell Division and Cancer Group of the Spanish National Cancer Research Centre (CNIO), led by researcher Marcos Malumbres, has developed a new, simple and fast technology that enhances in vitro and in vivo the potential of stem cells to differentiate into adult cells. The research results are published in The EMBO Journal.

In recent years, several protocols have been proposed to obtain reprogrammed stem cells in the laboratory from adult cells, but very few to improve the cells we already have. The method we developed is able to significantly increase the quality of stem cells obtained by any other protocol, thus favouring the efficiency of the production of specialised cell types, says Mara Salazar-Roa, researcher at the CNIO, first author of the article and co-corresponding author.

In this study, the researchers identified an RNA sequence, called microRNA 203, which is found in the earliest embryonic stages before the embryo implants in the womb and when stem cells still have their maximum capacity to generate all the different tissues. When they added this molecule to stem cells in the laboratory, they discovered that the cells ability to convert to other cell types improved significantly.

To corroborate this, they used stem cells of human and murine origin, and of genetically modified mice. The results were spectacular, both in mouse cells and in human cells. Application of this microRNA for just 5 days boosts the potential of stem cells in all scenarios we tested and improves their ability to become other specialised cells, even months after having been in contact with the microRNA, says Salazar-Roa.

According to the study, cells modified by this new protocol are more efficient in generating functional cardiac cells, opening the door to an improved generation of different cell types necessary for the treatment of degenerative diseases.

Malumbres, head of the CNIO Cell and Cancer Division Group, says: To bring this asset to the clinic, collaboration with laboratories or companies that want to exploit this technology is now necessary in each specific case. In this context, Salazar-Roa recently participated, in close collaboration with the CNIOs Innovation team, in prestigious innovation programs such as IDEA2 Global of the Massachusetts Institute of Technology (MIT) and CaixaImpulse of the la Caixa Foundation, from which they also obtained funding to start the development of this technology.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Go here to read the rest:
Quick and Simple Technology Enhances the Potential of Stem Cells To Differentiate Into Adult Cells - Technology Networks

Stem Cell Banking Market Global Industry Analysis and Opportunity and Forecast 2018 to 2028 – Cole of Duty

Global Stem Cell Banking Market: Overview

The demand within the global stem cell banking market is growing on account of advancements in the field of regenerative medicine. The medical fraternity has become extremely focused towards the development of artificial tissues that can infuse with the human body. Furthermore, medical analysis and testing has gathered momentum across biological laboratories and research institutes. Henceforth, it is integral to develop stem cell samples and repositories that hold relevance in modern-day research. The need for regenerative medicine emerges from the growing incidence of internal tissue rupture. Certain types of tissues do not recover for several years, and may even be damaged permanently. Therefore, the need for stem cell banking is expected to grow at a significant pace.

Download Brochure of This Market Report at https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6111

In a custom report, TMR Research digs into the factors that have aided the growth of the global stem cell banking market. The global stem cell banking market can be segmented on the basis of bank size, application, and region. The commendable developments that have incepted across the US healthcare industry has given a thrust to the growth of the North America stem cell banking market.

Global Stem Cell Banking Market: Notable Developments

The need for improved regenerative medication and anatomy has played an integral role in driving fresh developments within the stem cell banking market.

Gallant has emerged as a notable market entity that has remained as the torchbearer of innovation within the global stem cell banking market. The company has recently launched stem cell banking for dogs, and has attracted the attention of the masses. As people become increasingly concerned about their pets, the new move by Gallant shall help the company in earning the trust of the consumers. Moreover, it can move several notches higher on the innovation index.

Cells4Life has also remained at the forefront of developments within the global stem cell banking market. After suffering backlash for its error in cord blood stem cell promotion, the company is expected to use effective public relation strategies to regain its value in the market.

Global Stem Cell Banking Market: Growth Drivers

Development of improved facilities for storage of stem cells has played an integral role in driving market demand. Furthermore, the unprecedented demand for improved analysis of regenerative medications has also created new opportunities within the global stem cell banking market. Medical research has attracted investments from global investors and stakeholders. The tremendous level of resilience shown by biological researchers to develop stem cell samples has aided market growth. Henceforth, the total volume of revenues within the global stem cell banking market is slated to multiply.

Commercialization of stem cell banks has emerged as matter of concern for the healthcare industry. However, this trend has also helped in easy storage and procurement of cells stored during the yester years of children. Presence of sound procedures to register at stem cell banks, and the safety offered by these entities, has generated fresh demand within the global market. New regional territories are opening to the idea of stem cell banking. Several factors are responsible for the growth of this trend. Primarily, improvements in stem cell banking can have favourable impact on the growth of the healthcare industry. Moreover, the opportunities for revenue generation associated with the development of functional stem cell banks has aided regional market growth.

The global stem cell banking market is segmented on the basis of:

Source

Request For TOC On this Market Report at https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6111

See more here:
Stem Cell Banking Market Global Industry Analysis and Opportunity and Forecast 2018 to 2028 - Cole of Duty

Props To You, Californians: A Preview Of What’s On Your November Ballot – KPBS

After a bit of last-minute legislative maneuvering, the list of propositions that California voters will be asked to weigh in on has been more or less finalized.

This past week marked the deadline for citizens and special interests to snag their spot on the November ballot. Eight measures made the cut. They address matters as vital and/or esoteric as rent control, property tax law, dialysis clinic staffing requirements, stem cell research funding and the preservation or final dispatch of cash bail in California.

The same date also marked the deadline for legislators to place their preferred measures on the November ballot. But lawmakers have a bit more flexibility when it comes to deadlines they can just make new laws. On Monday, the Senate passed Senate Bill 300 to Gov. Gavin Newsom who signed it. The law effectively extended the Legislatures deadline to July 1.

(Technically, the deadline wasnt extended but created anew. The law calls for the Legislatures favored measures to go before voters in a whole new election conveniently to take place on the same day and same ballot as the ordinary November 3 election.)

That extension gave lawmakers a few extra hours to add four measures: two to expand voting rights, one that ends a 22-year-old ban on affirmative action, and one that is a tortuously complicated property tax measure that somehow ropes in Realtors, wildland firefighters and The Dude from the Big Lebowski.

Heres your November ballot preview:

These three measures, all placed on the ballot by the Legislature, had been introduced before protests against racism and police brutality swept the country. But as California lawmakers look for ways to play a role in the national debate about institutional barriers to equity and the meaning of citizenship, many legislators see these as particularly potent causes.

Prop. 16: Ending the ban on affirmative action

Who put it there: The Legislature, via a bill by San Diego Democrat Assemblymember Shirley Weber

Type: Constitutional amendment

What it would do: Allow schools and public agencies to take race and other immutable characteristics into account when making admission, hiring or contracting decisions.

In 1996 California voters passed Proposition 209, a constitutional amendment banning affirmative action at state institutions. The result was an immediate drop in Black and Latino enrollment at the states elite public universities. Some civil rights organizations have been trying to repeal Prop. 209 ever since.

Each of those attempts has been stymied by a coalition of Republicans, moderate Democrats and some progressive legislators who represent districts with large Asian American voting populations. This year, as in previous years, some of the most vocal and persistent opponents of the effort to reintroduce affirmative action have been Chinese-American political activists. They argue that boosting enrollment of students from underrepresented racial groups would come at the expense of overrepresented Asian American students.

Prop. 17: Restoring the right to vote to people on parole

Who put it there: The Legislature, via a bill by Sacramento Democrat Assemblymember Kevin McCarty.

Type: Constitutional amendment

What it would do: Allow Californians who are currently on parole to vote.

In 1974, California voters passed a ballot measure giving people who have committed felonies the right to vote once they complete their sentences and are no longer on parole.

Thanks to that law, there are some 40,000 Californians who are not in prison but unable to legally cast a ballot. But as with any criminal justice debate, this is also one about race. According to an estimate from 2016, two thirds of people on parole in the state are Latino or Black.

Prop. 18: Letting (some) 17 year olds vote (some of the time)

Who put it there: The Legislature, with a bill introduced by San Mateo Democrat Assemblymember Kevin Mullin.

Type: Constitutional amendment

What it would do: Allow 17-year-old U.S. citizens to vote in a primary and special election as long as they will turn 18 by the subsequent general election.

California Democrats have been on a decade-long tear increasing voting access. Same-day voter registration, automatic registration at the DMV and pre-registration of 16- and 17-year-olds are among the recent pro-vote innovations to come out of the Capitol.

Letting people under 18 vote would be yet another extension. Already 23 states let 17- year-olds vote in certain circumstances.

Democratic legislators have tried to do this six times before; this is the first to make the ballot.

This wouldnt be a California election without at least a few wildy contentious ballot measures about housing and property taxes.

Prop. 15: Split roll

Who put it there: Citizens. Campaign largely funded by the California Teachers Association, SEIU California and the Chan Zuckerberg Initiative.

Type: Constitutional amendment

What it would do: Tax some commercial property based on its market value, rather than the price at which it was purchased. This would raise property taxes on many large businesses across the state, increasing funding for schools and local government.

In 1978, California voters passed Proposition 13, placing a cap on property taxes, kicking off a nationwide anti-tax revolt and placing city and county budgets in a generation-spanning straitjacket.

By tying a landlords property tax payments to the original purchase price, Prop. 13 has been the gift that keeps on giving to property owners, particularly those lucky enough to have bought cheap real estate decades ago. Theres been bipartisan reluctance among lawmakers to touch it ever since, lest they incur the wrath of irate homeowners.

This initiative attempts to divide and conquer that political problem by repealing the property tax protections only for commercial landlords with more than $3 million in holdings. If this measure passes, those landowners would have to make tax payments based on the current value of their properties a tax hike for most resulting in an estimated $6.5 to $11.5 billion more for cities, counties and school districts.

Prop. 19: Property tax breaks and closing the Lebowski loophole

Who put it there: The Legislature, via a bill by San Mateo Democrat Assemblymember Kevin Mullin, but sponsored by the California Realtors.

Type: Constitutional amendment

What it would do: Allow homeowners who are over 55, disabled or victims of natural disaster to take a portion of their property tax base with them when they sell their home and buy a new one. It would also limit the ability of new homeowners who inherit properties to keep their parents or grandparents low property tax payments. Most of the additional money raised would go into a state fire response fund.

Weve seen this one before half of it, anyway. In 2018, the California Association of Realtors put a measure on the ballot allowing older or disabled homeowners to keep a portion of their Prop. 13 tax break. The Realtors argued that the current property tax rules disincentivize longtime homeowners from moving, trapping empty-nesters in houses that are too big for them and locking out new families. But because the measure would cost schools, counties and cities, it was opposed by organized labor and local government groups and failed by 20 points.

The Realtors tried again this year, but with an added fiscal sweetener. Under this proposal, anyone who inherits a home from their parents or grandparents would only be allowed to keep the low property taxes if they use the home as their primary residence and only on the first $1 million between the homes original purchase price and its market value. Inspiration for that caveat may have come from the Los Angeles Times, which tracked down a number of California scions, including The Big Lebowski star Jeff Bridges, who are still paying 1970-era property tax levels on their rental properties.

And then there was a last-minute wrinkle. In the final weeks of June, the Realtors sprang a deal: designating that most of the funding generated by the measure would go to fighting wildfires. That won the support of the influential California Professional Firefighters union. It also means the measure will be funding a public need that might be on many voters minds come November.

That bargain was struck after the Realtors had submitted their signatures, so with the help of Assemblyman Mullin, they passed it through the Legislature, pulling their original proposal just before the deadline.

Who put it on the ballot: Signatures, collected via an effort mostly funded by the AIDS Healthcare Foundation.

Type: Statute

What it would do: Allow cities to introduce new rent control laws, or expand existing ones.

Despite a 20-percentage point, 56-out-of-58 county defeat in 2018, a statewide rent control measure is back on the ballot.

Polling from that election season suggested that California voters generally liked rent control as a concept, but worried about the specifics of the proposal. Accordingly, this new initiative makes a few tweaks.

Under this one, cities would be allowed to apply new rent control ordinances only to homes that are at least 15 years old. And it exempts single-family homes owned by landlords with no more than two properties.

Just like last time, the measure is being pushed by the Los Angeles-based AIDS Healthcare Foundation and its pugnacious president Michael Weinstein. State lawmakers by passing a law last year that set a 7% ceiling on how much landlords can raise rents each year had hoped to ward off another attempt by Weinstein and company. They had no such luck.

California, the home of three-strikes sentencing, has spent the last decade rethinking its approach to criminal justice. Two measures on the November ballot, channeling the spirit of the 90s, are pushing to reverse that reversal.

Prop. 25: Ditch or keep cash bail

Who put it there: Signatures, via a campaign largely funded by the bail bond industry.

Type: Referendum

What it would do: Ask voters to either approve or strike down a state law that banished money bail from the state criminal justice system.

In 2018, acting on the advice of state Supreme Court Chief Justice Tani Cantil-Sakauye, legislators passed a bill ending cash bail in California. Rather than letting people pay their way out of jail while they await trial, the law gives judges the right to determine whether someone who is arrested should be kept behind bars based on the risk they are deemed to pose to themselves or others.

Moving quickly, the bail bond industry mounted a campaign to put the question on the ballot as a referendum. Voters will vote either Yes to keep the state law and end cash bail for good, making California the first state to do so, or No to keep the bail system.

Prop. 20: Rolling back Brown-era leniency

Who put it there: Signatures, via a campaign largely funded by law enforcement agencies.

Type: Constitutional amendment

What it would do: Allow prosecutors to charge repeat or organized petty theft as a felony, require probation officers to seek tougher penalties for those who violate the term of their parole three times, and exclude those who have been convicted of domestic violence and certain nonviolent crimes from early parole consideration.

Gov. Jerry Brown was famously allergic to talk of his legacy while in office. But if the former governor has one, it might be the effort he spent in his final two terms as governor supporting efforts to reverse the tough on crime policies he helped introduce during his first two terms in the 1970s and 80s.

In 2011, California legislators reduced punishments for parole violators. In 2014, voters passed Proposition 47, recategorizing some non-violent crimes as misdemeanors. In 2016, voters passed Proposition 57, giving inmates convicted of certain non-violent offenses a shot at early release.

This ballot measure would partially undo each of those.

Usually standoffs between employees and their bosses take place behind closed doors. In California, you often find them on the ballot.

Prop. 22: Self-employment for ride-hail and other app-drivers

Who put it there: Signatures, via a campaign mostly funded by Lyft, Uber and Doordash

Type: Statute

What it would do: Turn app-based drivers into independent contractors, exempting companies such as Lyft and Uber from standard wage and hour restrictions. It would also guarantee these drivers an earnings floor, a stipend to purchase health insurance and other minimum benefits.

Unless you happen to be an anti-vaccine protestor, the most controversial law of the 2019 legislative session was Assembly Bill 5. On its face, the law simply codified a state Supreme Court ruling, making it much harder for companies to treat their workers as independent contractors, rather than full-fledged employees. In practice, it upended the business models of Uber, Lyft, Doordash, Postmates and Instacart, all of which rely on an army of phone-toting gig-workers to provide their various services.

In the months since, all attempts at legislative compromise have fizzled, Californias Attorney General has sued Uber and Lyft for violating the new law and California regulators declared their drivers to be employees.

As a last-ditch effort, the various companies implicated have poured $110 million and counting to push a ballot measure that would simply exclude their drivers from the law. And throwing a bone to critics who say their drivers are mistreated, the measure also imposes some worker benefits and protections.

Prop. 23: Regulating dialysis clinics

Who put it there: Signatures, via an effort funded entirely by the Service Employees International Union-United Healthcare Workers West

Type: Statute

What it would do: Require dialysis clinics to have at least one physician on site at all times and to report patient infection data to California health officials.

DaVita Kidney Care and Fresenius Medical Care own the majority of the for-profit dialysis clinics in the state. For years, the Service Employees International Union-United Healthcare Workers union has been at war with them.

After unsuccessful efforts to unionize clinic staff, the union sponsored legislation to cap reimbursement rates to clinics and floated an array of possible ballot measures to boost their staff spending and cut their profits. In 2018, the union finally got one on the ballot: Prop 8, which would have set a cap on clinic profit margins.

The measure was soundly defeated, but only after the two companies spent over $111 million, making it the most expensive ballot campaign ever. This one isnt likely to be much cheaper.

Two measures on this years ballot aim to bolster laws and programs already on the books. Both campaigns are led by Bay Area real estate developers with a penchant for ballot box policymaking.

Prop. 24: Stronger consumer privacy laws (again)

Who put it there: Signatures, via a campaign funded entirely by Alastair and Celine Mactaggart.

Type: Statute

What it would do: Strengthen Californias already strongest-in-the-nation consumer privacy law and establish a California Privacy Protection Agency

In 2018, California lawmakers passed the California Consumer Privacy Act, giving consumers the right to find out what data companies are collecting about them, to opt out of having it collected and to have that data scrubbed. It was and remains the only law like it in the county. It was also a compromise. San Francisco real estate developer Alastair MacTaggart had been pushing for an even stricter ballot measure, but the Legislature stepped in, brokering a deal between MacTaggart and the tech industry.

Now MacTaggart is back. Along with setting up a state agency tasked with enforcing state privacy law, the measure would beef up financial penalties for violators and allow consumers to demand that personal information not be shared at all, rather than simply not sold.

Who put it there: Signatures via an effort mostly funded by Robert Klein, JDRF International and Open Philanthropy

Type: Bond

What it would do: Borrow $5.5 billion to fund stem cell research

In 2004, voters passed Proposition 71 to create the California Institute for Regenerative Medicine. The institute exists to channel state money toward stem cell research. Prop 71 also let the state borrow $3 billion to do that.

That pot of cash is now almost empty. Robert Klein, a Silicon Valley real estate developer who led the Prop. 71 effort and became the institutes first board chair, is leading the campaign for more.

Correction: This story has been corrected to reflect that Robert Klein was the first board chair of the California Institute for Regenerative Medicine.

The California Dream Project is a statewide collaboration focused on issues of economic opportunity, quality-of-life, and the future of the California Dream. Partner organizations include CALmatters, Capital Public Radio, KPBS, KPCC, and KQED.

KPBS' daily news podcast covering local politics, education, health, environment, the border and more. New episodes are ready weekday mornings so you can listen on your morning commute.

To view PDF documents, Download Acrobat Reader.

More here:
Props To You, Californians: A Preview Of What's On Your November Ballot - KPBS